New targeted therapies in breast cancer

被引：0

作者：

Coussy, F. ^{[1
]}

Teixeira, L. ^{[1
,2
]}

Giacchetti, S. ^{[1
]}

Cuvier, C. ^{[1
]}

Hocini, H. ^{[1
]}

Espie, M. ^{[1
,2
]}

机构：

[1] Hop St Louis, Ctr Malad Sein, F-75010 Paris, France

[2] Univ Paris 07, F-75010 Paris, France

来源：

GYNECOLOGIE OBSTETRIQUE & FERTILITE | 2014年 / 42卷 / 11期

关键词：

Breast cancer; Targeted therapies; Survival; PHASE-II TRIAL; BEVACIZUMAB-CONTAINING THERAPY; TAXANE-BASED CHEMOTHERAPY; OPEN-LABEL; GROWTH-FACTOR; NEOADJUVANT CHEMOTHERAPY; ADJUVANT TRASTUZUMAB; 1ST-LINE BEVACIZUMAB; DOUBLE-BLIND; VEGF-TRAP;

D O I：

10.1016/j.gyobfe.2014.09.007

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Trastuzumab improves care of patients with HER2+ breast cancer and allows a major gain in terms of survival. T-DM1 and pertuzumab are two new treatments, which give very encouraging results in metastatic breast cancer. Their place in neo-adjuvant and adjuvant setting still remains to be defined. Bevacizumab have its place in metastatic breast cancer. In adjuvant setting, results are disappointing and in neo-adjuvant setting, we need more studies on subgroups, which can benefit more. Development of the PARP inhibitors was slowed down by recent negative results in metastatic breast cancer but studies continue with more targeted patient's. Finally, everolimus, inhibitor of mTOR, allows to by pass the hormono-resistance in metastatic phase. Its toxicity must be taken into account in particular in adjuvant setting. (C) 2014 Elsevier Masson SAS. All rights reserved.

引用

页码：787 / 794

页数：8

共 54 条

[1] Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial [J].

Andre, Fabrice ;

O'Regan, Ruth ;

Ozguroglu, Mustafa ;

Toi, Masakazu ;

Xu, Binghe ;

Jerusalem, Guy ;

Masuda, Norikazu ;

Wilks, Sharon ;

Arena, Francis ;

Isaacs, Claudine ;

Yap, Yoon-Sim ;

Papai, Zsuzsanna ;

Lang, Istvan ;

Armstrong, Anne ;

Lerzo, Guillermo ;

White, Michelle ;

Shen, Kunwei ;

Litton, Jennifer ;

Chen, David ;

Zhang, Yufen ;

Ali, Shyanne ;

Taran, Tetiana ;

Gianni, Luca .

LANCET ONCOLOGY, 2014, 15 (06) :580-591

[2] A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair [J].

Ashworth, Alan .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3785-3790

[3] Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study [J].

Bachelot, Thomas ;

Bourgier, Celine ;

Cropet, Claire ;

Ray-Coquard, Isabelle ;

Ferrero, Jean-Marc ;

Freyer, Gilles ;

Abadie-Lacourtoisie, Sophie ;

Eymard, Jean-Christophe ;

Debled, Marc ;

Spaeth, Dominique ;

Legouffe, Eric ;

Allouache, Djelila ;

El Kouri, Claude ;

Pujade-Lauraine, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (22) :2718-2724

[4] Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer [J].

Baselga, Jose ;

Martins Segalla, Jose Getulio ;

Roche, Henri ;

del Giglio, Auro ;

Pinczowski, Helio ;

Ciruelos, Eva M. ;

Cabral Filho, Sebastiao ;

Gomez, Patricia ;

Van Eyll, Brigitte ;

Bermejo, Begona ;

Llombart, Antonio ;

Garicochea, Bernardo ;

Climent Duran, Miguel Angel ;

Gehm Hoff, Paulo Marcelo ;

Espie, Marc ;

Junior Gemeinder de Moraes, Andre Augusto ;

Ribeiro, Ronaldo Albuquerque ;

Mathias, Clarissa ;

Gil Gil, Miguel ;

Ojeda, Belen ;

Morales, Josefa ;

Ro, Sunhee Kwon ;

Li, Shell ;

Costa, Frederico .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (13) :1484-1491

[5] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [J].

Baselga, Jose ;

Bradbury, Ian ;

Eidtmann, Holger ;

Di Cosimo, Serena ;

de Azambuja, Evandro ;

Aura, Claudia ;

Gomez, Henry ;

Dinh, Phuong ;

Fauria, Karine ;

Van Dooren, Veerle ;

Aktan, Gursel ;

Goldhirsch, Aron ;

Chang, Tsai-Wang ;

Horvath, Zsolt ;

Coccia-Portugal, Maria ;

Domont, Julien ;

Tseng, Ling-Min ;

Kunz, Georg ;

Sohn, Joo Hyuk ;

Semiglazov, Vladimir ;

Lerzo, Guillermo ;

Palacova, Marketa ;

Probachai, Volodymyr ;

Pusztai, Lajos ;

Untch, Michael ;

Gelber, Richard D. ;

Piccart-Gebhart, Martine .

LANCET, 2012, 379 (9816) :633-640

[6] Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer [J].

Baselga, Jose ;

Semiglazov, Vladimir ;

van Dam, Peter ;

Manikhas, Alexey ;

Bellet, Meritxell ;

Mayordomo, Jose ;

Campone, Mario ;

Kubista, Ernst ;

Greil, Richard ;

Bianchi, Giulia ;

Steinseifer, Jutta ;

Molloy, Betty ;

Tokaji, Erika ;

Gardner, Humphrey ;

Phillips, Penny ;

Stumm, Michael ;

Lane, Heidi A. ;

Dixon, J. Michael ;

Jonat, Walter ;

Rugo, Hope S. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) :2630-2637

[7] Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer [J].

Bear, Harry D. ;

Tang, Gong ;

Rastogi, Priya ;

Geyer, Charles E., Jr. ;

Robidoux, Andre ;

Atkins, James N. ;

Baez-Diaz, Luis ;

Brufsky, Adam M. ;

Mehta, Rita S. ;

Fehrenbacher, Louis ;

Young, James A. ;

Senecal, Francis M. ;

Gaur, Rakesh ;

Margolese, Richard G. ;

Adams, Paul T. ;

Gross, Howard M. ;

Costantino, Joseph P. ;

Swain, Sandra M. ;

Mamounas, Eleftherios P. ;

Wolmark, Norman .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (04) :310-320

[8] First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study [J].

Bergh, Jonas ;

Bondarenko, Igor M. ;

Lichinitser, Mikhail R. ;

Liljegren, Annelie ;

Greil, Richard ;

Voytko, Nataliya L. ;

Makhson, Anatoly N. ;

Cortes, Javier ;

Lortholary, Alain ;

Bischoff, Joachim ;

Chan, Arlene ;

Delaloge, Suzette ;

Huang, Xin ;

Kern, Kenneth A. ;

Giorgetti, Carla .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (09) :921-929

[9] Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer [J].

Blackwell, Kimberly L. ;

Burstein, Harold J. ;

Storniolo, Anna Maria ;

Rugo, Hope ;

Sledge, George ;

Koehler, Maria ;

Ellis, Catherine ;

Casey, Michelle ;

Vukelja, Svetislava ;

Bischoff, Joachim ;

Baselga, Jose ;

O'Shaughnessy, Joyce .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1124-1130

[10] Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study [J].

Bowles, Erin J. Aiello ;

Wellman, Robert ;

Feigelson, Heather Spencer ;

Onitilo, Adedayo A. ;

Freedman, Andrew N. ;

Delate, Thomas ;

Allen, Larry A. ;

Nekhlyudov, Larissa ;

Goddard, Katrina A. B. ;

Davis, Robert L. ;

Habel, Laurel A. ;

Yood, Marianne Ulcickas ;

McCarty, Catherine ;

Magid, David J. ;

Wagner, Edward H. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (17) :1293-1305

← 1 2 3 4 5 6 →